In a phase 2b trial published Oct. 26, 2026, in JAMA, one intranasal dose of mebufotenin cut depression scores more than a very low dose at day 29 in adults with treatment-resistant depression, and most people were ready to go…
A meta-analysis of sixteen randomized trials with 1992 participants found that psychodynamic psychotherapy lasting at least nine months reduced depressive symptoms compared with other conditions, with effects generally sustained.
Pooling double-blind trials in adults with depression, escitalopram and amitriptyline lengthened the QTc interval, a heart rhythm measure, more than placebo. Antidepressants were not linked to more early major heart events.